Milciclib-mediated CDK2 inhibition to boost radiotherapy sensitivity in colorectal cancer

Milciclib-mediated CDK2 inhibition to boost radiotherapy sensitivity in colorectal cancer

BackgroundColorectal cancer (CRC) ranks as the third most common cancer globally. Neoadjuvant radiotherapy is the standard treatment for locally advanced rectal cancer; however, primary or acquired resistance often leads to treatment failure. Identifying new targets to overcome radiotherapy resistan...

Full description

Saved in:
Bibliographic Details
Main Authors: Junjie Ma, Shanshan Wu, Xinxin Yang, Shuying Shen, Yiqian Zhu, Ruoqi Wang, Wei Xu, Yue Li, Haixin Zhu, Youyou Yan, Nengming Lin, Bo Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
Milciclib
CDK2 inhibitor
colorectal cancer
radiotherapy resistance
DNA repair
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1557925/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1557925/full

Similar Items